Overview

Hypoglycemia and the Mineralocorticoid Receptor

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Robert Wood Johnson Foundation
Treatments:
Eplerenone
Mineralocorticoids
Spironolactone